Structured Abstract
BACKGROUND Familial Alzheimer’s disease (fAD) is heterogeneous in terms of age at onset and clinical presentation. A greater understanding of the pathogenicity of fAD variants and how these contribute to heterogeneity will enhance our understanding of the mechanisms of Alzheimer’s disease more widely. The pathogenicity of the P436S mutation in PSEN1 remains unclassified.
METHODS To determine the pathogenicity of the PSEN1 P436S mutation, we studied an expanded kindred of 8 affected individuals, with MRI (2 individuals), patient-derived iPSC models (2 donors) and post-mortem histology (1 donor).
RESULTS An autosomal dominant pattern of inheritance of fAD was seen with an average age at symptom onset of 46 years and atypical features including late spastic paraparesis and non-memory led cognitive impairment in some individuals. iPSC models and post- mortem tissue supported high production of Aβ43. PSEN1 peptide maturation was unimpaired, unlike previously reported atypical mutations R278I and E280G. CONCLUSIONS: We confirm that the P436S mutation in PSEN1 causes atypical fAD. The location of the mutation in the critical PSEN1 PALP motif may explain the early age of onset despite appropriate protein maturation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CA was supported by an Alzheimer's Society fellowship (AS-JF-18-008). SW was supported by senior research fellowship from Alzheimer's Research UK (ARUK-SRF2016B-2). FT was supported by an EMBO scientific exchange grant (No. 9297). RG was part of the of the UCL Neurogenetic Therapies Programme, generously funded by The Sigrid Rausing Trust. YB is supported by the Association of Frontotemporal Dementia. NSR was supported by a University of London Chadburn Academic Clinical Lectureship. This work was supported by the Medical Research Council (MR/M02492X/1), the UK Dementia Research Institute at UCL (which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society and ARUK), and by the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The National Research Ethics Committee Service committee at Queen Square gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
